Zacks: Analysts Anticipate Gemphire Therapeutics Inc (GEMP) Will Announce Earnings of -$0.42 Per Share

Wall Street brokerages expect Gemphire Therapeutics Inc (NASDAQ:GEMP) to report ($0.42) earnings per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Gemphire Therapeutics’ earnings. Gemphire Therapeutics reported earnings per share of ($0.58) during the same quarter last year, which would indicate a positive year over year growth rate of 27.6%. The company is scheduled to report its next quarterly earnings report on Tuesday, May 14th.

According to Zacks, analysts expect that Gemphire Therapeutics will report full year earnings of ($1.59) per share for the current financial year. For the next year, analysts anticipate that the business will report earnings of ($3.55) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Gemphire Therapeutics.

Gemphire Therapeutics (NASDAQ:GEMP) last announced its quarterly earnings results on Friday, March 15th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.15.

A number of research analysts have weighed in on the stock. Zacks Investment Research cut shares of Gemphire Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, April 11th. ValuEngine lowered shares of Gemphire Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, January 24th. Five equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $14.90.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Virtu Financial LLC purchased a new stake in shares of Gemphire Therapeutics during the fourth quarter valued at approximately $27,000. Cary Street Partner Investment Advisory LLC bought a new stake in shares of Gemphire Therapeutics in the fourth quarter worth $212,000. Finally, BlackRock Inc. increased its stake in shares of Gemphire Therapeutics by 2,210.5% in the third quarter. BlackRock Inc. now owns 675,038 shares of the company’s stock worth $1,391,000 after buying an additional 645,822 shares during the last quarter. Institutional investors own 27.17% of the company’s stock.

GEMP stock traded up $0.03 during midday trading on Wednesday, reaching $1.36. 462 shares of the company’s stock traded hands, compared to its average volume of 41,526. The stock has a market cap of $18.98 million, a price-to-earnings ratio of -0.80 and a beta of 3.04. Gemphire Therapeutics has a fifty-two week low of $0.57 and a fifty-two week high of $11.43.

About Gemphire Therapeutics

Gemphire Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH). It is developing gemcabene, a novel, once-daily, oral therapy, for high risk cardiovascular patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy, and for those patients who present with NASH.

Recommended Story: What is the Moving Average Convergence Divergence (MACD) oscillator?

Get a free copy of the Zacks research report on Gemphire Therapeutics (GEMP)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Gemphire Therapeutics (NASDAQ:GEMP)

Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with's FREE daily email newsletter.